MARKET

ADVM

ADVM

Adverum Biotech
NASDAQ
1.970
-0.010
-0.51%
After Hours: 1.930 -0.04 -2.03% 19:41 03/01 EST
OPEN
1.980
PREV CLOSE
1.980
HIGH
2.020
LOW
1.910
VOLUME
1.01M
TURNOVER
0
52 WEEK HIGH
2.970
52 WEEK LOW
0.6810
MARKET CAP
199.02M
P/E (TTM)
-1.5690
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ADVM last week (0219-0223)?
Weekly Report · 6d ago
Review Of The Developmental Landscape Of Long-Acting Anti-VEGF Therapies In Wet-AMD
Seeking Alpha · 02/20 01:42
Weekly Report: what happened at ADVM last week (0212-0216)?
Weekly Report · 02/19 09:55
Adverum Biotech: Statement of changes in beneficial ownership of securities
Press release · 02/14 23:10
Weekly Report: what happened at ADVM last week (0205-0209)?
Weekly Report · 02/12 09:51
Wall Street Breakfast: The Week Ahead
Seeking Alpha · 02/11 09:35
Catalyst Watch: Coca-Cola earnings, Instacart lockup, 13F filings and more NYCB drama
Seeking Alpha's Catalyst Watch includes a breakdown of next week's key events. Coca-Cola, SeaWorld, and Microsoft among companies due to report next week. Options trading volume and short interest are still high on New York Community Bancorp. The CPI report for January is expected to be released.
Seeking Alpha · 02/09 20:00
Adverum’s Ixoberogene Soroparvovec Shows Promise in LUNA Trial
TipRanks · 02/09 09:20
More
About ADVM
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein for ocular diseases. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration (wet AMD) who are responsive to anti-VEGF therapy. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection.

Webull offers Adverum Biotechnologies Inc stock information, including NASDAQ: ADVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADVM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADVM stock methods without spending real money on the virtual paper trading platform.